Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Pigment Cell & Melanoma Research|June 22, 2011
Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunityJasper G van den Boorn, Cornelis J Melief, Rosalie M LuitenCurrent Pharmaceutical Design|May 18, 2012
Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigenRenee Vermeij, Ninke Leffers, Cornelis J Melief, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 11, 2010
Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formationMarieke F Fransen, Marianne J van Stipdonk, Marjolein Sluijter, et al.Oncoimmunology|January 23, 2015
Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one moleculeGijs G Zom, Dmitri V Filippov, Gijsbert A van der Marel, et al.Journal of Liposome Research|March 23, 2011
Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomesMyrra G Carstens, Koen van der Maaden, Daniel van der Velden, et al.Immunity|December 19, 2006
Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitinationGuillaume van Niel, Richard Wubbolts, Toine Ten Broeke, et al.Proceedings of the National Academy of Sciences of the United States of America|April 7, 2009
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacityNadine van Montfoort, Marcel G Camps, Selina Khan, et al.International Journal of Cancer|December 6, 2011
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II studyRenee Vermeij, Ninke Leffers, Baukje-Nynke Hoogeboom, et al.JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.Science Translational Medicine|April 15, 2016
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responsesMarij J Welters, Tetje C van der Sluis, Hélène van Meir, et al.Pageof 2